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Abstract  
Septic cardiomyopathy is a life-threatening organ dysfunction caused by sepsis. Ribonuclease 
1 (RNase 1) belongs to a group of host-defense peptides that specifically cleave extracellular 
RNA (eRNA). The activity of RNase1 is inhibited by ribonuclease-inhibitor 1 (RNH1). The 
role of RNase 1 in septic cardiomyopathy and associated cardiac apoptosis, however, is 
completely unknown. Here, we showed that sepsis resulted in a significant increase in RNH1 
and eRNA serum levels compared to those of healthy subjects (p < 0.05). Treatment with RNase 
1 resulted in a significant decrease of apoptosis, induced by the intrinsic pathway, and TNF 
expression in murine cardiomyocytes exposed to either necrotic cardiomyocytes or serum of 
septic patients for 16 h (p < 0.05). Furthermore, treatment of septic mice with RNase 1 resulted 
in a reduction in cardiac apoptosis, TNF expression and septic cardiomyopathy (p < 0.05). 
These data demonstrate that eRNA plays a crucial role in the pathophysiology of the organ 
(cardiac) dysfunction in sepsis and RNase and RNH1 may be new therapeutic targets/strategies 
to reduce the cardiac injury and dysfunction caused by sepsis. 
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Introduction 
Sepsis is one of the most common causes of death on intensive care units and is defined as a 
life-threatening organ dysfunction secondary to an infection (1, 2). In addition to respiratory 
failure, septic cardiomyopathy is a common organ dysfunction in septic shock and is clearly 
associated with prolonged hospital stays and increased mortality (3, 4). Septic cardiomyopathy 
is a functional restriction of the heart that results in a ventricular dilation and reduced 
contractility (5, 6). To date, however, no specific therapeutic strategies are available.  
The tissue injury associated with sepsis results in the release of a variety of damage-associated 
molecular patterns (DAMPs) (7, 8). Extracellular RNA (eRNA) belongs to this heterogeneous 
group of DAMPs and includes several types of RNA present in the extracellular environment 
including micro RNA (miRNA), transfer RNA (tRNA), small interfering RNA (siRNA), and 
long non-coding RNA (lncRNA). The eRNA is released as a result of tissue injury and necrotic 
cell death from a variety of cells including cardiomyocytes (9) and may play a role in 
differentiation, chromatin modification, inflammation as well as tissue injury and repair (10-
14). It is, however, not known whether eRNA plays a role in septic cardiomyopathy and cardiac 
apoptosis. Playing a decisive role in septic cardiomyopathy (15), apoptosis represents a 
programmed, caspase-mediated cell death that is triggered by intrinsic or extrinsic signaling 
pathways. 
In 1988, Steven Benner described eRNA as an intercellular “communicator” and hypothesized 
that their activity is modulated by endogenous ribonucleases (RNases) (16). RNases belong to 
a group of host-defense peptides, which are ubiquitously expressed in several tissues and body 
fluids. As a part of the innate immune system, RNases modulate local and systemic 
inflammatory responses induced by exogenous pathogens and endogenous danger molecules 
(17). Specifically, RNase 1 cleaves eRNA and, hence, modulates/limits the levels of circulating 
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eRNA (17). As an endogenous modulator of RNase 1, the human ribonuclease-inhibitor 1 
(RNH1) is ubiquitously expressed in a variety of tissues and binds to and inactivates RNase 1 
with a high affinity (18, 19). RNH1 and RNase 1 have complementary structures (20). Primarily 
induced by oxidative stress (20), RNH1 regulates the activity of RNases and, thus, plays a 
crucial role in the immunomodulatory and host-defense functions of RNases (21). The 
respective roles of RNase 1 and RNH1 in septic cardiomyopathy and cardiac apoptosis, 
however, are completely unknown. 
The aim of this reverse-translational study was to investigate a) the levels and kinetics of RNH1 
and the eRNA profile in the serum of patients with sepsis and healthy subjects (control), b) the 
potential of RNase 1 to reduce apoptosis in cardiomyocytes and c) whether the application of 
RNase 1 attenuates septic cardiomyopathy and cardiac apoptosis in a murine model of 
polymicrobial sepsis. 
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Results 
RNH1 is elevated in serum of septic patients 
We recently reported that serum levels of RNase 1 are significantly elevated in the early phase 
of sepsis (22). As RNH1 inhibits the enzymatic activity of RNase 1, we have now investigated 
the serum levels of RNH1 in septic patients (n = 21) on the day of diagnosis and three days 
after diagnosis. Moreover, we analyzed serum levels of RNH1 in healthy subjects (n = 10) 
matched in age and gender. The characteristics of the study population according to the groups 
are shown in Table 1 in the supplemental material. In healthy subjects, the RNH1 concentrations 
were below the detection limit of the ELISA used (1.563 ng/ml; n = 10; Figure 1A). In contrast, 
a mean concentration of 4.22 ± 1.00 ng/ml RNH1 was detected in the serum of septic patients 
at time of diagnosis (Figure 1A), which rose further to 5.29 ± 1.36 ng/ml at three days after 
diagnosis of sepsis (p < 0.05 when compared to healthy subjects; Figure 1A). 
Levels of eRNA are elevated in serum of septic patients  
Having discovered elevated serum levels of RNase 1 and of its inhibitor RNH1 in patients with 
sepsis, we then measured the levels of eRNA in serum of septic patients three days after 
diagnosis (n = 21) and healthy volunteers (n = 10). Furthermore, we investigated the different 
sizes of eRNA presented in serum of septic patients and healthy volunteers. A mean 
concentration of 59.64 ± 4.92 ng/µl eRNA was measured in healthy subjects. In contrast, in 
serum of septic patients three days after diagnosis a significantly increased mean concentration 
of 105.6 ± 4.85 ng/µl eRNA was detected (p < 0.05 when compared to healthy subjects; Figure 
1B). The electropherograms from serum of septic patients three days after diagnosis (n = 21) 
showed a higher variety of eRNA compared to heathy subjects (n = 10; Figure 1C). In healthy 
volunteers, a more uniform eRNA size distribution was observed, with the highest sample 
6 
 
intensity in the serum of healthy volunteers lying between 100 and 500 nt. In contrast, the serum 
of septic patients showed a much higher variance in eRNA size distribution and a much higher 
sample intensity, which is caused by the higher concentration of eRNA in the serum of septic 
patients (Figure 1C). 
RNase 1 reduces the caspase 3 activation and apoptosis induced by necrotic cardiomyocytes 
Septic cardiomyopathy is associated with cardiac apoptosis and necrotic cell death (23, 24). We 
investigated the potential induction of apoptosis by eRNA released from necrotic 
cardiomyocytes by exposing murine cardiomyocytes to necrotic cardiomyocytes. We also 
investigated whether RNase 1 reduces the degree of apoptosis caused by the eRNA released 
from necrotic cardiomyocytes. Cardiomyocytes exposed to necrotic cardiomyocytes, in the 
absence of RNase 1 treatment, showed a significant increase of cleaved/activated caspase 3 
when compared to unstimulated cells as measured by immunofluorescence (p < 0.01; Figure 
2A and B). Treatment with RNase 1, however, resulted in a decrease in caspase 3 activation (p 
< 0.05; Figure 2A and B). As eRNA leads to an increased expression of tumor necrosis factor 
alpha (TNF) via binding to toll-like receptor (TLR) 3 and 7 (23-25), we investigated TNF 
mRNA expression in this setting. Indeed, we found that cardiomyocytes stimulated with 
necrotic cardiomyocytes in the presence of RNase 1 showed a significant reduction in the 
expression of TNF mRNA when compared to cardiomyocytes challenged with necrotic 
cardiomyocytes in the absence of RNase 1 (p < 0.05; Figure 2C). Furthermore, we investigated 
the amount of the total eRNA released from 105 NC/ml and from the cell supernatants of 
unstimulated/stimulated cardiomyocytes. In cell supernatant of untreated cardiomyocytes, the 
mean concentration of eRNA was 0.85 ± 0.07 ng/ml. In contrast, we found significantly 
increased eRNA concentrations in the supernatant of cardiomyocytes exposed to necrotic 
cardiomyocytes for 16 h (1.17 ± 0.03 ng/ml) as well as in 105 necrotic cells/ml (1.15 ± 0.07 
ng/ml; p < 0.05; Figure 2D). 
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Next, we aimed to confirm that apoptosis was the predominant type of cell death in 
cardiomyocytes exposed to necrotic cardiomyocytes by TUNEL labelling. Unstimulated 
cardiomyocytes (control) did not show any TUNEL fluorescence (Figure 3A). In 
cardiomyocytes exposed to necrotic cardiomyocytes for 16 h, however, there was an increased 
number of TUNEL positive cells (significant increase of a mean 3.58 ± 0.47 relative TUNEL 
fluorescence compared to unstimulated cells; p < 0.001; Figure 3A and B). In contrast, the 
exposure of cardiomyocytes to necrotic cells in the presence of RNase 1 resulted in a smaller 
number of TUNEL positive cells (mean 1.91 ± 0.42 relative TUNEL fluorescence compared to 
cardiomyocytes exposed to necrotic cells in absence of RNase; Figure 3A and B).  
 
The amount of apoptosis was further quantified/confirmed using flow cytometry. Relatively 
few unstimulated cells were positive for Annexin V (7.57 ± 0.36%), 7-AAD (0.97 ± 0.30%) 
and Annexin V plus 7-AAD (0.54 ± 0.12%). The main part of the population was represented 
by living cells (Figure 3C). Cardiomyocytes exposed to 1x105 necrotic cardiomyocytes 
contained 13.36 ± 2.17% Annexin V, 1.26 ± 0.12% 7-AAD and 0.51 ± 0.01% Annexin V and 
7-AAD positive cells (Figure 3C). The exposure of necrotic cardiomyocytes in presence of 
RNase 1, however, resulted in 7.55 ± 1.09% Annexin V, 0.82 ± 0.21% 7-AAD and 0.96 ± 
0.77% Annexin V and 7-AAD positive cells (Figure 3C). The amount of Annexin V positive 
cells significantly increased in cardiomyocytes exposed to necrotic cardiomyocytes compared 
to unstimulated cells (p < 0.001; Figure 3D), which was significantly diminished by the addition 
of RNase 1 (p < 0.001; Figure 3D). 
RNase 1 reduces the caspase 3 activation induced by serum of septic patients 
Having found that serum levels of RNH1 as well as total eRNA are significantly elevated in 
serum of septic patients, we investigated caspase 3 activation and TNF mRNA expression in 
murine cardiomyocytes challenged with serum of septic patients, as a reverse translational 
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approach. Specifically, we aimed to confirm the potential protective/anti-apoptotic effect of 
RNase 1 in this setting. When compared to unstimulated cells, cardiomyocytes exposed to 
serum of septic patients (in the absence of RNase 1) showed a significant increase in the 
cleavage of caspase 3 as well as an increase in the expression of TNF mRNA (p < 0.05; Figure 
4A, B and C). In contrast, RNase 1 attenuated the increases in both caspase 3 activation and 
TNF mRNA expression in cardiomyocytes challenged with serum of septic patients (p < 0.05; 
Figure 4A, B and C).  
TLR3 inhibition reduces the caspase 3 activation induced by eRNA 
Having shown that apoptosis and TNF expression were induced by necrotic cardiomyocytes 
and serum of septic patients which both contain eRNA, we next investigated caspase 3 
activation in cardiomyocytes challenged with eRNA isolated from cardiomyocytes. We 
detected a significantly increased relative caspase 3 activation in cardiomyocytes exposed to 
eRNA, when compared to unstimulated cardiomyocytes (1.26 ± 0.08; p < 0.05; Figure 4D). 
Furthermore, we wanted to investigate whether caspase 3 activation in cardiomyocytes exposed 
to eRNA is caused by binding to TLR3. Indeed, we found a decreased relative caspase 3 
activation in cardiomyocytes stimulated with eRNA in presence of a TLR3 inhibitor (CU CPT 
4a) compared to cardiomyocytes exposed to eRNA in the absence of the TLR3 inhibitor (1.10 
± 0.11; Figure 4D).  
Ribonuclease improves the cardiovascular function and reduces cardiac apoptosis in murine 
polymicrobial sepsis 
Having shown that the exposure of murine cardiomyocytes in presence of RNase 1 resulted in 
reduced apoptosis (when challenged with necrotic cardiomyocytes or serum of septic patients), 
we next investigated the effect of RNase 1 on cardiac function and cardiac apoptosis in a murine 
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model of polymicrobial sepsis. When compared to sham-operated mice, CLP-sepsis resulted in 
a substantial cardiac dysfunction (measured as a reduction of ejection fraction (EF), fractional 
shortening (FS) and fractional area change (FAC) by echocardiography) (all p < 0.001; Figure 
5). Treatment with RNase 1, however, significantly attenuated the cardiac dysfunction 
associated with CLP-sepsis, as indicated by higher values of EF, FS (both p < 0.001; Figure 5) 
and FAC (p < 0.01; Figure 5) compared to vehicle-treated CLP-mice (control). In order to 
analyze the cardiac dysfunction in sepsis and the potential beneficial effects of RNase 1, we 
further investigated the left ventricular end-diastolic volume (LVEDV), left ventricular end-
systolic volume (LVESV) and stroke volume (SV) as well as the cardiac output and the heart 
rate before echocardiography. Of note, no change in LVEDV was detected between the groups 
(Figure 5E). In CLP-sepsis, a significant increased LVESV was measured, when compared to 
sham-operated mice (p < 0.01; Figure 5). RNase 1 treatment of CLP-animals, however, resulted 
in a decrease of LVESV (when compared to vehicle-treated CLP-sepsis). Accordingly, when 
compared to sham-operated mice, CLP-sepsis resulted in a significant decreased SV, heart rate 
and cardiac output, which was significantly diminished by RNase 1 treatment (all p < 0.01; 
Figure 5). Sham operated animals treated with RNase 1 showed no changes in any of the above 
parameters, when compared to sham-operated animals treated with vehicle (Figure 5). 
To gain a better understanding of the underlying signaling events involved in the observed 
beneficial effects of RNase 1 on sepsis-associated cardiomyopathy, we investigated the relevant 
apoptosis pathways in cardiac tissue at 24 h after onset of sepsis (e.g. the time point at which 
cardiac function was evaluated). When compared to sham-operated animals, CLP-sepsis 
resulted in a significant increase in Bax levels as well as caspase 9 and caspase 3 activation (p 
< 0.001; p < 0.01; p < 0.01; Figure 6). In contrast to vehicle-treated animals, the treatment of 
CLP-mice with RNase 1, however, significantly attenuated the increases in Bax levels and the 
associated activation of caspase 9 and caspase 3 associated with sepsis (p < 0.01; p < 0.01; p < 
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0.05; Figure 6). Furthermore, CLP-sepsis resulted in a decrease in Bcl-2 levels in the heart (p < 
0.05; Figure 6), an effect which was also significantly attenuated by RNase 1 treatment (p < 
0.01; Figure 6). To confirm that apoptosis is induced by CLP in the heart, we analyzed the 
number of apoptotic cells in heart tissue by TUNEL labelling. When compared to sham-
operated animals, CLP-sepsis resulted in an increase in relative TUNEL fluorescence (mean 
2.73 ± 0.71 relative TUNEL fluorescence; Figure 6E and F). The treatment of CLP-sepsis with 
RNase 1 resulted in a decreased of relative TUNEL fluorescence compared to vehicle-treated 
CLP-animals (mean 1.45 ± 0.60 relative TUNEL fluorescence; Figure 6E and F). Treatment of 
sham operated mice with RNase 1 did not result in an increase in TUNEL fluorescence (mean 
0.64 ± 0.26 relative TUNEL fluorescence; Figure 6E and F).  
Having discovered elevated serum levels of RNH1 and total eRNA in patients with sepsis, we 
also investigated the serum levels of RNase 1, RNH1 and total eRNA in murine polymicrobial 
sepsis. We also analyzed the TNF serum levels in CLP-sepsis in order to gain a better 
understanding of the underlying mechanisms and associations between the eRNA concentration 
and the pro-inflammatory/pro-apoptotic cardiac response. In sham-operated mice treated with 
vehicle or RNase 1, RNase 1 serum levels were 236.86 ± 8.11 ng/ml and 287.32 ± 19.37 ng/ml 
(Figure 7B). In contrast, untreated sepsis (24 hours after CLP-challenge) resulted in 
significantly decreased RNase 1 serum levels (69.68 ± 27.16 ng/ml RNase 1; p < 0.05 when 
compared to sham operated mice; Figure 7B), while septic mice treated with RNase 1 showed 
a mean RNase 1 concentration of 108.5 ± 22.70 ng/ml (Figure 7B). In sham-operated mice 
treated with vehicle, the TNF and RNH1 concentrations were below the detection limit of the 
ELISA used (31.3 pg/ml and 0.78 ng/ml; Figure 7A and C). CLP-animals showed TNF and 
RNH1 concentrations of 215.4 ± 57.86 pg/ml and 4.68 ± 0.73 ng/ml, respectively (both n = 8; 
Figure 7A and C). When compared to vehicle-treated animals, the treatment with RNase 1, 
however, resulted in decrease in the concentrations of TNF (41.1 ± 17.90 pg/ml; p < 0.05; 
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Figure 7A) and RNH1 (3.83 ± 1.15 ng/ml; Figure 7C). In addition, we found a significant 
correlation between TNF and RNase 1 concentration in CLP-mice treated with vehicle or 
RNase 1 (both p < 0.05; Figure 7F and G). Figure 7D shows the corresponding eRNA levels of 
the individual groups (Figure 7D).To gain a better understanding of the RNase 1 expression in 
sepsis, we performed a time course of RNase 1 serum levels in CLP-sepsis (Figure 7E). We 
detected a significant decrease of RNase 1 serum levels in CLP-sepsis compared to sham 
operated mice at all time points (all p < 0.05; Figure 7E). The highest RNase 1 serum levels in 
CLP-sepsis could be measured 1 h after sepsis induction by CLP (177.21 ± 62.78). We detected 
the lowest RNase 1 serum levels at 3 h after surgery (11.43 ± 1.20), with the levels increasing 
again (52.14 ± 18.59) at 24 h after surgery.  
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Discussion 
Septic cardiomyopathy is a life-threatening organ dysfunction associated with a complicated 
postoperative course and increased mortality. Despite intense efforts in basic and clinical 
research, the therapy of this condition is supportive in nature, as no specific therapy is available 
(5). This urgently necessitates a better understanding of the underlying pathophysiology and 
most importantly, the identification of new therapeutic targets and strategies. This study 
provides the first evidence that RNase 1 reduces cardiac apoptosis and attenuates septic 
cardiomyopathy by reducing the levels of circulating eRNA in a murine model of polymicrobial 
sepsis.  
Specifically, we report here for the first time that the levels of RNH1, the endogenous inhibitor 
of RNase 1, are significantly elevated on the day of diagnosis and three days after diagnosis of 
sepsis (Figure 1A). We have also recently reported an increased serum expression of RNase 1 
at the onset of sepsis (22). RNH1 specifically binds to RNase 1 and inhibits its activity (20). 
Based on these findings, we hypothesized that an increase in RNH1 expression results in an 
increase of eRNA levels, due to inhibition of the enzymatic activity of RNase 1 by RNH1 
(Figure 8). Indeed, we found significantly elevated levels of free circulating eRNA in the serum 
of septic patients (Figure 1B). The tissue injury and cell death in sepsis and septic shock leads 
to a loss of tissue integrity and subsequently to the release of both cell-free DNA and eRNA 
into the circulation (26). Although there is good evidence that cell-free DNA plays a crucial 
role in the crosstalk between tissue injury, inflammation, and coagulation, only very little is 
known about the physiological and pathophysiological roles of eRNA in sepsis (27). It has been 
suggested that the negative charge of eRNA builds the structural feature rendering eRNA 
capable of activating factor XII and, hence, coagulation (28, 29). Moreover, Chen and 
colleagues report that eRNA contributes to myocardial inflammation via TLR-3-Trif signaling 
(23). Whether or not eRNA plays a role in cardiac apoptosis, which plays a pivotal role in the 
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pathophysiology of septic cardiomyopathy, however, was not known. To address this important 
question, we exposed cardiomyocytes to necrotic cardiomyocytes or serum of septic shock 
patients (Figure 2, 3 and 5). In line with the work from Chen and colleagues, we used necrotic 
cardiomyocytes (as our source of eRNA) to stimulate cardiomyocytes with eRNA (23). This 
approach enabled us to expose cardiomyocytes to the eRNA contained in cardiomyocytes, 
which contain several types of RNA (e.g. miRNA, tRNA and siRNA) (10). In addition to the 
free circulating, extracellular RNA, in both stimulants (necrotic cardiomyocytes and serum of 
septic patients) a part of the RNA may be encapsulated in extracellular vesicles such as 
exosomes or microvesicles and, thus, be protected from the digestion of RNase 1 (30, 31). 
Nevertheless, we were able to show that RNase 1 significantly reduces both apoptosis and 
inflammation in murine cardiomyocytes (Figure 2, 3 and 4). To standardize our model, we first 
measured the total amount of eRNA in the cell supernatant of cardiomyocytes exposed to 
necrotic cardiomyocytes (Figure 2D). In fact, we found an increased release of eRNA into the 
cell supernatant of cardiomyocytes exposed to necrotic cardiomyocytes compared to the cell 
supernatant of untreated cardiomyocytes (Figure 2D). We further found a significant activation 
(measured as cleavage) of caspase 3 and consecutive induction of apoptosis by exposing murine 
cardiomyocytes to either necrotic cardiomyocytes or, of note, serum of septic patients (Figure 
2 and 4). Furthermore, to address the question as to whether the observed increase in apoptosis 
is caused by eRNA, we exposed cardiomyocytes to eRNA isolated from cardiomyocytes. 
Indeed, we found a significantly increase in caspase 3 activation in cardiomyocytes challenged 
with eRNA compared to unstimulated cells (Figure 4D). In line to Chen and colleagues, we 
showed that eRNA contributes to induction of apoptosis (caspase 3 activation) via TLR3 
signaling (Figure 4D) (23). Having shown that sepsis is associated with elevated RNH1 levels, 
we next aimed to investigate the potential protective/therapeutic effects of RNase 1.  
We report here for the first time that RNase 1 attenuates caspase 3 activation and apoptosis in 
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cardiomyocytes exposed to either necrotic cardiomyocytes or, as a reverse translational 
approach, to the serum of septic patients. Previous studies have investigated the therapeutic 
potential of a reduction/inhibition of apoptosis by direct/specific caspase-inhibition in animal 
models of cardiomyopathy induced by ischemia/reperfusion and rapid ventricular pacing (32, 
33). Cabrera-Fuentes et al. reported that RNase 1 treatment reduces the infarct size caused by 
myocardial ischemia/reperfusion (34). Furthermore, they measured a reduction in necrotic cell 
death in ischemic hearts treated with RNase 1 compared vehicle-treatment (34). In addition, 
there is also good evidence that eRNA released from necrotic cells triggers the release of pro-
inflammatory cytokines, while RNase1 reduces the formation of cytokines (23, 24), which play 
a key role in septic cardiomyopathy and cardiac apoptosis (35, 36). We report here that RNase 
1 attenuates TNF mRNA expression in cardiomyocytes exposed to either necrotic 
cardiomyocytes or serum of septic patients. Thus, RNase 1 may attenuate septic 
cardiomyopathy by reducing both cardiac apoptosis and cytokine production. 
In order to gain a better insight into the roles of RNH1, RNase 1 and eRNA in septic 
cardiomyopathy in vivo, we used a murine model of polymicrobial sepsis. Having shown 
increased serum levels of RNase 1 in patients at the early phase (onset) of sepsis (22), we here 
detected significantly lower RNase 1 serum levels in CLP-mice (at 24 h after onset of sepsis). 
The very short half-life of RNase 1 as well as the inhibition of RNase 1 by RNH1 may all be 
reasons, which either individually or in combination contribute to the differences observed. In 
line with our findings in human sepsis, we found that the levels of RNH1 are significantly 
elevated in mice with polymicrobial sepsis (Figure 7C). Based on these findings, we propose 
that an increase in RNH1 expression results in a decreased RNase 1 expression/enzymatic 
activity, which results in an increase in circulating eRNA leading to a release of pro-
inflammatory cytokines (Figure 8). To substantiate this hypothesis, we have investigated the 
effect of RNase 1 as a therapeutic target on the cardiac dysfunction associated with sepsis. We 
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confirm that the model of polymicrobial sepsis used here, indeed, results in a significant cardiac 
dysfunction defined by a significant decrease in ejection fraction, fractional shortening and 
fraction area change (Figure 5). Stieger et al. reported a significant increase of fractional 
shortening in mice treated with RNase 1 (50 µg/kg) compared to mice treated with saline 24 h 
after myocardial infraction (37). In line, we detected a significant reduction in left ventricular 
cardiac dysfunction in CLP-mice treated with RNase 1 as determined by a significant increase 
in ejection fraction, fractional shortening, fraction area change and cardiac output (Figure 5). 
Moreover, we detected a significant reduction in the release of TNF in CLP-mice treated with 
RNase 1 when compared with CLP-mice treated with vehicle (Figure 7A). Additionally, we 
found a negative correlation between the RNase 1 and TNF concentration, higher RNase 1 
serum levels were associated with lower TNF levels (Figure 7E and F). These findings support 
the hypothesis that eRNA released from necrotic cells triggers the release of pro-inflammatory 
cytokines, while RNase 1 reduces the formation of cytokines by cleaving eRNA (Figure 8). 
Notably, treatment of CLP-mice with RNase 1 reduced the cardiac dysfunction associated with 
sepsis.  
We also investigated the sepsis-associated degree of cardiac apoptosis in our murine model of 
polymicrobial sepsis. The induction of apoptosis can be triggered by either the intrinsic or the 
extrinsic pathway. Several studies have shown that cytochrome C and Apaf-1 form an 
apoptosome which activates caspase 9 (38), which, in turn, activates caspase 3. Activated 
caspase 3 then initiates and drives apoptosis. Indeed, we observed a significant activation of the 
intrinsic apoptosis signaling pathway in murine hearts from mice with polymicrobial sepsis, 
indicated by a significant increase in Bax levels, activation of caspase 9 and caspase 3 and a 
decrease of Bcl-2 (Figure 6). Furthermore, we measured increased apoptosis induction in heart 
tissue by TUNEL-labeling (Figure 6). In line with our findings, Hotchkiss et al. reported as 
early as 1999 that apoptosis in the spleen of septic patients also occurs through the intrinsic 
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apoptosis pathway (39). Treatment of CLP-mice with RNase 1 resulted in a reduction of the 
activation of apoptosis in the heart. Most notably, treatment of septic mice with RNase 1 
attenuated the rise in cardiac Bax levels, activation of caspase 9 and caspase 3, the decrease in 
Bcl-2 and TUNEL-positive cells caused by sepsis in the heart (Figure 6). In line with our 
findings, Stieger et al. reported a reduction of apoptosis 24 h after ligation of the left anterior 
descending artery (LAD) in mice treated with RNase 1 (37). Treatment with RNase 1 in sham 
operated mice did not show any apoptosis induction (Figure 6). These results indicate that 
excessive amounts of eRNA drive apoptosis in the heart by activating the intrinsic apoptosis 
pathway. However, in contrast to the eRNA serum levels of septic patients, we could not detect 
any difference in eRNA expression in CLP-mice compared to sham operated mice (Figure 7D). 
One possible reason for the different results may be the different time points of the 
measurements: While eRNA concentration was measured in patients with sepsis three days 
after diagnosis, the concentration of eRNA in mice was measured 24 h after CLP-sepsis 
induction. This hypothesis is also confirmed by Stieger and colleagues, who reported increased 
eRNA levels within 30 min and maximal eRNA levels at 2 h after ligation of the LAD. 
However, 4 h after ligation of LAD, the eRNA levels had returned to baseline (37). 
In conclusion, our data show for the first time that sepsis results in a significant increase in 
eRNA and RNH1, the endogenous inhibitor of RNase 1. We found that RNase 1 reduces 
apoptosis as well as TNF expression in murine cardiomyocytes induced by necrotic 
cardiomyocytes or serum of septic patients. In addition, treatment with RNase 1 reduces the 
degree of a) cardiac apoptosis induced by the intrinsic pathway, b) TNF expression and c) the 
cardiac dysfunction caused by polymicrobial sepsis in mice. Based on these findings we 
propose that a) eRNA plays a significant role in the pathophysiology of the organ (cardiac) 
dysfunction in sepsis and b) RNase may be a new therapeutic strategy to reduce the cardiac 
injury and dysfunction caused by sepsis.  
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Materials and methods 
Study Population  
The blood samples of septic ICU patients (n = 21) were collected during the first 18 h and three 
days after diagnosis of sepsis defined by the 2012 Surviving Sepsis Campaign Guidelines using 
an intravascular catheter (40). Age and gender matched healthy subjects were used as control 
(n = 10). 
Serum sampling 
After 10 min of coagulation at room temperature, the serum samples were centrifuged at 2000 
g for 10 min and stored at -80 °C (22). The characteristics of the study population are shown in 
Table 1 according to the groups: healthy subjects, patient with sepsis on the day of diagnosis 
(Sepsi DD) and patients with sepsis three days after diagnosis (Sepsis D3). 
Enzyme-Linked Immunosorbent Assays (ELISA) 
The levels of the RNH1 and RNase 1 in human and mice serum were determined using a 
commercial ELISA kit (LifeSpan BioSciences, Seattle, Washington, USA). According to the 
manufacturer, no significant cross-reactivity or interference between Ribonuclease A / 
RNASE1 and analogues is known. Furthermore, the ELISAs do not distinguish between bound 
RNase 1 and unbound RNase 1 with RNH1. Mouse TNF-alpha DuoSet ELISA kit (R&D 
Systhems, Minneapolis, Minnesota, USA) was used to measure the TNF serum levels in mice. 
The optical density was measured at 450 nm using a microplate reader (Tecan Group, 
Männedorf, Switzerland). 
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Total eRNA analyzation and screening 
Total eRNA in serum of healthy subjects (n = 10) and septic patients three days after diagnosis 
(n = 21) were analyzed using QuantiFlour RNA System and Quantus Fluorometer (Promega, 
Madison, Wisconsin, USA). For RNA size quantification cell-free RNA was isolated from 
serum of healthy subjects and patients with sepsis by the Quick-cfRNA Serum & Plasma Kit 
(Zymo Research, Irvine, Kalifornien, USA). The 4200 TapStation system and the high 
sensitivity RNA ScreenTape Assay (Agilent, Santa Clara, Californian, USA) was used for 
analyzing the RNA molecules from 50-6000 nucleotides. 
Cell culture 
HL-1 cells, a mouse atrial cell line, were provided by Dr. Claycomb (Sigma-Aldrich, Munich, 
Germany) (41). Briefly, HL-1 cells were cultured on gelatin/fibronectin coated plates and 
maintained in Claycomb-Medium (Sigma-Aldrich, Munich, Germany) supplemented with 10% 
fetal calf serum (Biochrom, Berlin, Germany), 0.1 mM norepinephrine (Sigma-Aldrich, 
Munich, Germany), 2 mM L-glutamine (Sigma-Aldrich, Munich, Germany) and 1% 
penicillin/streptomycin (Invitrogen, Carlsbad, Californian, USA) under an atmosphere of 5% 
CO2 at 37°C (42-45). Cardiomyocytes were exposed to 1x10
5 necrotic cardiomyocytes per ml 
medium or to 5% serum of septic patients in the presence or absence of 2.8 U/ml RNase 1 
(Invitrogen) for 16 h. Unstimulated cells were used as negative control. 
Necrotic Cardiomyocytes  
Necrotic cardiomyocytes were generated as described recently, by three circles of freezing at -
80°C and thawing at 37°C (23). Necrosis was verified by trypan blue staining. Necrotic cells 
(1x106 cells/ml) were stored at -80°C.  
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RNA extraction of cardiomyocytes 
HL-1 cells were cultivated as described before and harvested by scraping (45). After three 
washing cycles with PBS the RNA was isolated using the NucleoSpin RNA Kit (Macherey-
Nagel, Düren, Germany).  
Cell stimulation 
Cardiomyocytes were exposed to 1x105 necrotic cardiomyocytes per ml medium or to 5% 
serum of septic patients in the presence or absence of 2.8 U/ml RNase 1 (Invitrogen) for 16 h. 
Unstimulated cells were used as negative control. Furthermore, cardiomyocytes were exposed 
to 100 ng/ml RNA in presence or absence of 2 µM CU CPT 4a (TLR3 inhibitor, Tocris 
Bioscience, Bristol, United Kingdom).  
Immunofluorescence of cleaved caspase 3 
The amount of cleaved caspase 3 was analyzed using immunofluorescence. As described 
previously (45), HL-1 cells were grown on coverslips and exposed to necrotic cardiomyocytes 
or serum of septic patients in presence or absence of 2.8 U/ml RNase 1 for 16 h. Afterwards, 
cells were fixed with 4% formaldehyde (Sigma-Aldrich, Munich, Germany) for 15 min at room 
temperature. After three times of washing using PBS, cells were blocked with blocking buffer 
(5% BSA and 0.3% Triton X-100 in PBS) for 1 h. The cardiomyocytes were, then, incubated 
with a primary antibody directed against cleaved caspase 3 (Cell signaling, Danvers, 
Massachusetts, USA), diluted 1:200 in antibody dilution buffer (1% BSA and 0.3% Triton X-
100 in PBS) over night at 4°C. After three washing cycles, the cardiomyocytes were incubated 
with a secondary antibody (Invitrogen, Carlsbad, California, USA) diluted 1:1000 in antibody 
dilution buffer for 2 h at room temperature in the dark. Coverslips were washed as described 
before and covered with ProLong Gold (Invitrogen, Carlsbad, California, USA) containing 4',6-
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diamidino-2-phenylindole (DAPI) for nuclei staining. Immunofluorescence was detected using 
LSM 710 confocal microscope (Zeiss, Oberkochen, Germany) and quantified by ImageJ 
software. 
TUNEL-labelling 
As described previously (45), HL-1 cells were grown in 12-well plates on coverslips coated 
with gelatin/fibronectin. HL-1 cells were fixed with 4% formaldehyde for 1 h at room 
temperature after exposure with necrotic cells in presence or absence of RNase 1 for 16 h. After 
washing, cells were permeabilized with 0.1% Triton X-100 for 2 min on ice. Next, cells were 
labeled using the In-Situ Cell Detection Kit TMR red (Roche, Mannheim, Germany) as 
described (45). Coverslips were covered with 15 µl ProLong Gold. Unstimulated cells were 
used as negative control. The paraffin embedded heart tissues were dewaxed by a series of 
alcohol and washed twice in PBS. The tissues were permeabilized in the microwave with 0.1 
M citrate buffer (pH 6.0) for 5 min by 350 W. After cooling down the tissues were labeled also 
using the In-Situ Cell Detection Kit TMR red (Roche, Mannheim, Germany) and covered with 
ProLong Gold. An LSM 710 confocal microscope (Zeiss, Oberkochen, Germany) and ImageJ 
software was used to detect and quantify apoptotic cells.  
Relative TNF mRNA expression 
RNA was isolated using Trizol reagent, as described before (45). The following primers were 
used to analyze the relative mRNA expression of TNF in the quantitative real-time PCR 
(StepOnePlus Real-Time PCR System; Thermo Fisher Scientific, MA, USA): TNF 5′ 
TCCCCAAAGGGATGAGAAG 3′ (for) and 5′ GCACCACTAGTTGGTTGTC 3′ (rev), S7 5′ 
GGTGGTCGGAAAGCTATCA 3′ (for) and 5′ AAGTCCTCAAGGATGGCGT 3′ (rev). 
Relative quantification was performed by using Microsoft Excel (Microsoft, Washington, DC, 
USA). 
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Flow cytometry 
The amount of cell death was analyzed as described before by using flow cytometry (45). 
Stimulated cardiomyocytes were harvested by scraping. After three washing cycles with PBS, 
the supernatant was discarded and cells were resuspended in binding buffer as described in the 
APC Annexin V Apoptosis Detection Kit (BD Pharming, New Jersey, USA). Cells were stained 
with APC Annexin V Apoptosis Detection Kit and analyzed by FACSCanto-II (BD 
Biosciences, New Jersey, USA). 
Caspase 3 activity 
To analyze the caspase 3 activity 1.5 × 104 cardiomyocytes/well were seeded in a 96-well white 
plate. After 24 h the cells were exposed with 100 µl medium containing RNA in presence and 
absence of TLR3 inhibitor. Untreated cells were used as negative control. The caspase 3 activity 
was analyzed by adding 100 µl of Caspase-Glo® 3/7 Assay reagent (Promega Corporation, 
Madison, Wisconsin, USA). The luminescence was detected after 30 min of incubation at room 
temperature using microplate reader (Tecan Group, Männedorf, Switzerland). 
Murine polymicrobial sepsis model 
For this study, ten-week old, male C57BL/6 mice were used. Cecal ligation and puncture (CLP) 
was performed to induce polymicrobial sepsis as previously described (46, 47). Surgery was 
performed under anesthesia by isoflurane (3%) delivered in oxygen at a rate of 1 l/min in an 
anesthetic chamber and maintained with isoflurane (2%) and oxygen (1 l/min) via a face mask. 
Buprenorphine (0.05 mg/kg, i.p.) was administered just before starting the surgery to obtain 
adequate analgesia. Under anesthesia, the abdomen was opened, the cecum was totally ligated 
below the ileocecal valve and punctured at both opposite ends using an 18-G needle, where a 
small amount of feces was squeezed out. As control, sham operated mice (without CLP) were 
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used. For fluid resuscitation, normal saline (0.9% NaCl) was administered into the mouse’s 
abdomen before closure (5 ml/kg) and administrated directly after surgery (10 ml/kg s.c.). 
Antibiotics (Imipenem/Cilastatin; 0.25 mg dissolved in fluid resuscitation 7.5 ml/kg 0.9% 
NaCl, s.c.) and analgesia (Buprenorphine; 0.05 mg/kg, i.p.) were injected 6 and 18 h after 
surgery. RNase 1 or its vehicle was administrated before sepsis induction (50 µg/kg RNase 1 
or 0.9% NaCl, i.v.), directly after surgery (200 µg/100 µl RNase 1 or 100 µl 0.9% NaCl, s.c.) 
and 4 h after surgery (500 µg/100 µl RNase 1 or 100 µl 0.9% NaCl, s.c.). The surgeon was 
blinded to vehicle or treatment group. After 24 h, cardiac function was assessed by 
echocardiography in vivo.  
Echocardiography  
Cardiac function was assessed 24 h after CLP on the Vevo 3100 imaging system (VisualSonics, 
Toronto, Ontario, Canada). Briefly mice were sedated in an anesthetic chamber with isoflurane 
(3%) delivered in oxygen at a rate of 1 l/min and then transferred onto a thermoregulatory 
platform in the supine position, where anesthetic was maintained at: isoflurane (0.5-2.0%) and 
oxygen (1 l/min). The fur was removed from the chest by Veet® hair removal cream and pre-
warmed echo gel was then placed onto the shaven chest, where the following parameters of 
cardiac function was measured via the MX550D imaging probe: percentage ejection fraction 
(EF %), percentage fractional shortening (FS %) and percentage fractional area change (FAC 
%). After sacrifice of the animals, the organs and blood were collected for further experiments. 
All analysis was conducted offline and blinded.  
Protein isolation and Western-Blot 
Semi-quantitative Western-Blot analysis of caspase 3, caspase 9, Bax and Bcl-2 was performed 
in murine heart tissue as described before (48, 49). For protein isolation, the tissue was 
23 
 
homogenized in homogenization buffer (20 mM HEPES (pH 7.9), 1 mM MgCl2, 0.5 mM 
EDTA, 1% Nonidet P-40, 1mM EGTA, 1 mM DTT, 0.5 mM PMSF, 1 µl/ml of PIC) and 
centrifuged by 18800 g for 40 min at 4°C. The protein concentration of the supernatant was 
determined using the bicinchoninic acid (BCA) protein assay (Thermo Fisher Scientific, MA, 
USA). Proteins were separated by size using sodium dodecyl sulfate polyacrylamide gel 
electrophoresis and transferred to polyvinylidene difluoride membrane. Unspecific bonds were 
blocked by incubating the membrane for one hour in blocking buffer (10% BSA in TBS 
containing 0.1% Tween). Following, the membrane was incubated with the primary antibody 
over night at 4°C diluted in 5% BSA in TBS containing 0.1% Tween. After three washing 
cycles, the membrane was incubated for 30 min with the HRP-conjugated secondary antibody. 
Protein bands were detected with enhanced chemiluminescent (ECL) detection system. The 
immunoreactive bands were visualized by autoradiography and the densitometric analysis was 
performed using Gel Pro Analyzer 4.5, 2000 software (Media Cybernetics, Silver Spring, MD, 
USA). Results were normalized by using Tubulin as an endogenous control. The following 
primary antibodies from Cell Signaling were used: caspase-9 (C9) mouse (#9508), Bcl-2 
(D17C4) rabbit (#3498), caspase-3 rabbit (#9662), Bax (D3R2M) rabbit (#14796). 
Statistical analysis of the measurements 
The statistical analysis and the graphs were performed with GraphPad Prism 7 (GraphPad Inc., 
San Diego, California, USA). A one-way ANOVA followed by Bonferroni test or unpaired t-
test (two-tailed) were used for multiple comparisons with a significance level of p < 0.05. The 
data represent the mean ± SEM of three independent experiments. 
Study approval 
All serum samples were collected in a study carried out by the Department of Intensive Care 
and Intermediate Care at University Hospital RWTH Aachen and were stored in the centralized 
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biomaterial bank (RWTH cBMB) after informed consent of all study participants and approval 
by the local ethics committee (EK 206/09). 
The Animal Welfare Ethics Review Board of the Queen Mary University of London approved 
the animal experimental protocols used in this study (Procedure Project License: PC5F29685). 
Animal care was in accordance with the guidelines of the Home Office guidance on Operation 
of Animals (Scientific Procedures Act 1986) published by Her Majesty’s Stationery Office and 
the Guide for the Care and Use of Laboratory Animals of the National Research Council.  
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Figures 
Figure 1 
 
RNH1 and total extracellular RNA serum levels  
(A) RNH1 levels of healthy subjects (n = 10) and ICU patients with sepsis on the day of 
diagnosis (Sepsis DD) and three days after diagnosis (Sepsis D3; both n = 21) are displayed. A 
one-way ANOVA followed by Bonferroni test was used for multiple comparisons. Data are 
presented as dot plot with the mean ± SEM. (B) Total eRNA levels from serum of healthy 
subjects (n = 10) and septic patients three days after diagnosis (n = 21) are demonstrated. An 
unpaired t-test (two-tailed) was used for statistical analysis. Data are presented as dot plot with 
the mean ± SEM.  (C) The eRNA size distribution from serum of healthy subjects (n = 10) and 
septic patients three days after diagnosis (n = 21) are presented in an electropherogram and a 
gel image. The first peak (between 10 and 100 nt) of the electropherograms represented the 
ladder. §p < 0.05 vs control/healthy; RNH1 = ribonuclease-inhibitor 1; eRNA = extracellular 
RNA  
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Figure 2 
 
RNase 1 treatment results in decrease of cleaved caspase 3 immunofluorescence and TNF 
mRNA expression in murine cardiomyocytes exposed to necrotic cardiomyocytes 
(A) Cardiomyocytes exposed to 105 necrotic cardiomyocytes (NC) for 16 h in presence (RNase 
+ NC) or absence of 2.8 U/ml RNase 1 were stained with Phalloidin, DAPI and anti-cleaved 
caspase 3 and compared to unstimulated cells (control). Phalloidin represents the cytosol (red), 
DAPI stained the nuclei (blue) and the green immunofluorescence represents the cleaved 
caspase 3 (cl. caspase 3) expression. Scale bars: 100 μm. (B) Quantification of cleaved caspase 
3 immunofluorescence (all n = 3). A one-way ANOVA followed by Bonferroni test was used 
for multiple comparisons. Data are presented as dot plot with the mean ± SEM. (C) Relative 
TNF mRNA expression of cardiomyocytes exposed to NC in presence of RNase 1 compared to 
cardiomyocytes stimulated in absence of RNase 1 (both n = 3). An unpaired t-test (two-tailed) 
was used for statistical analysis. Data are presented as dot plot with the mean ± SEM.  (D) Total 
extracellular RNA in cell supernatant of cardiomyocytes exposed to NC for 16 h and untreated 
cells (both n = 3) as well as eRNA level in 105 NC/ml (n = 2). A one-way ANOVA followed 
by Bonferroni test was used for multiple comparisons. Data are presented as dot plot with the 
mean ± SEM. §p < 0.05 vs control; #p < 0.05 vs NC; DAPI = 4',6-diamidino-2-phenylindole; 
NC = necrotic cardiomyocytes; RNase = ribonuclease 1  
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Figure 3 
 
RNase 1 treatment of cardiomyocytes exposed to necrotic cardiomyocytes results in 
decreased apoptosis  
Cardiomyocytes exposed to 105 necrotic cardiomyocytes in presence (RNase + NC) or absence 
(NC) of 2.8 U/ml RNase 1 for 16 h compared to unstimulated cells (control) were analyzed (all 
n = 3). (A) Apoptotic cells were labeled with TUNEL (red) and the nuclei of cardiomyocytes 
stained with DAPI (blue). Scale bars: 100 μm. (B) Quantification of TUNEL fluorescence. A 
one-way ANOVA followed by Bonferroni test was used for multiple comparisons. Data are 
presented as dot plot with the mean ± SEM. (C) Treated HL-1 cells were stained with Annexin 
V and 7-AAD and analyzed by flow cytometry. Gate I (lower left) displays the living cells. The 
Annexin V positive cells are shown in Gate II (top left) and represent the apoptotic 
cardiomyocytes. The double positive cells are demonstrated in Gate III (top right) and in Gate 
IV (lower right) the 7-AAD positive or necrotic cells are located. (D) The percentage of 
Annexin V positive (apoptotic) cells are displayed. A one-way ANOVA followed by 
Bonferroni test was used for multiple comparisons. Data are presented as dot plot with the mean 
± SEM. §p < 0.05 vs control; #p < 0.05 vs NC; NC = necrotic cardiomyocytes; RNase = 
ribonuclease 1; DAPI = 4',6-diamidino-2-phenylindole; TUNEL = TdT-mediated dUTP-biotin 
nick end labeling  
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Figure 4 
 
RNase 1 treatment or TLR3 inhibition results in decrease of caspase 3 activation and TNF 
expression in murine cardiomyocytes exposed to serum of septic patients or RNA 
(A) Cardiomyocytes exposed to 5 % serum of patients with sepsis (SsP) for 16 h in presence 
(RNase + SsP; n = 4) or absence of 2.8 U/ml RNase 1 (n = 3) were stained with DAPI and anti-
cleaved caspase 3 and compared to unstimulated cells (control; n = 3). DAPI stained the nuclei 
(blue) and the green immunofluorescence represents the cleaved caspase 3 (cl. caspase 3) 
expression. Scale bars: 50 μm. (B) Quantification of cleaved caspase 3 immunofluorescence. A 
one-way ANOVA followed by Bonferroni test was used for multiple comparisons. Data are 
presented as dot plot with the mean ± SEM. (C) Relative TNF mRNA expression of 
cardiomyocytes exposed to SsP in presence of RNase 1 compared to cardiomyocytes stimulated 
in absence of RNase 1 (both n =3). An unpaired t-test (two-tailed) was used for statistical 
analysis. Data are presented as dot plot with the mean ± SEM. (D) Relative caspase activity was 
analyzed in cardiomyocytes exposed to 100 ng/ml eRNA and unstimulated cells for 16 h in 
presence (both n = 3) or absence (both n = 5) of 2 µM TLR3-Inhibitor using Caspase Glo assay. 
A one-way ANOVA followed by Bonferroni test was used for multiple comparisons. Data are 
presented as dot plot with the mean ± SEM. §p < 0.05 vs control; #p < 0.05 vs SsP; DAPI = 4',6-
diamidino-2-phenylindole; SsP = serum of septic patients; RNase = ribonuclease 1  
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Figure 5 
 
RNase 1 treatment of mice with polymicrobial sepsis resulted in an improved heart 
function 
(A) Representative echocardiography images of each group are shown. (B) The ejection 
fraction, (C) fractional shortening, (D) fraction area change, (E) left ventricular end-diastolic 
volume (LVEDV), (F) left ventricular end-systolic volume (LVESV), (G) stroke volume (SV), 
(H) cardiac output and (I) heart rate before echocardiography of sham operated mice treated 
with vehicle (n = 12) or RNase 1 (n = 5) and mice with polymicrobial sepsis induced by CLP 
treated with vehicle or RNase 1 were analyzed (both n = 12). Individual values are plotted as 
mean ± SEM. A one-way ANOVA followed by Bonferroni test was used for multiple 
comparisons (graph B-I). §p < 0.05 vs Sham; #p < 0.05 vs CLP + Vehicle; CLP = cecal ligation 
and puncture; RNase = ribonuclease 1 
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Figure 6 
 
RNase 1 treatment of mice with polymicrobial sepsis resulted in a decreased cardiac 
apoptosis 
Heart tissue of sham operated mice (n = 4) or mice with polymicrobial sepsis induced by CLP 
treated with vehicle or RNase 1 (both n = 5) were analyzed by Western Blot. To analyze the 
intrinsic apoptosis signaling pathway, (A) Bax and (B) Bcl-2 levels as well as (C) caspase 9 
and (D) caspase 3 activation were investigated. A one-way ANOVA followed by Bonferroni 
test was used for multiple comparisons. Data are presented as dot plot with the mean ± SEM. 
Representative immunoblots are presented above the bar charts. The quantified OD of bands 
was corrected for the corresponding tubulin bands and normalized using the related sham band. 
Heart tissue of sham operated mice treated with vehicle or RNase or mice with polymicrobial 
sepsis induced by CLP also treated with vehicle or RNase 1 (all n = 5) were analyzed by 
TUNEL-labelling. (E) Apoptotic cells were labeled with TUNEL (red) and the nuclei of 
cardiomyocytes stained with DAPI (blue). Scale bars: 100 μm. (F) Quantification of TUNEL 
fluorescence. A one-way ANOVA followed by Bonferroni test was used for multiple 
comparisons. Data are presented as dot plot with the mean ± SEM.  §p < 0.05 vs Sham; #p < 
0.05 vs CLP + Vehicle; CLP = cecal ligation and puncture; RNase = ribonuclease 1; Bcl-2 = 
B-cell lymphoma 2  
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Figure 7 
 
RNase 1 treatment of mice with polymicrobial sepsis resulted in a decreased TNF 
expression 
(A) TNF, (B) RNase 1 and (C) RNH1 serum levels of sham operated mice treated with vehicle 
(n = 11) or RNase 1 (n = 5) or mice with polymicrobial sepsis induced by CLP treated with 
vehicle (n = 8) or RNase 1  (n = 9) were analyzed by ELISA. An unpaired t-test (two-tailed) 
was used for statistical analysis (graph A and C). In graph B, a one-way ANOVA followed by 
Bonferroni test was used for multiple comparisons. Data are presented as dot plot with the mean 
± SEM. (D) Total extracellular RNA in serum of mice are demonstrated. A one-way ANOVA 
followed by Bonferroni test was used for multiple comparisons. Data are presented as dot plot 
with the mean ± SEM. (E) RNase 1 serum levels over the time in sham operated mice (n = 3) 
and mice with polymicrobial sepsis induced by CLP treated with vehicle (n = 4). Correlation of 
TNF and RNase 1 of mice with polymicrobial sepsis induced by CLP (F) treated with vehicle 
and (G) treated with RNase 1. §p < 0.05 vs Sham; #p < 0.05 vs CLP + Vehicle; CLP = cecal 
ligation and puncture; RNase = ribonuclease 1; RNH1 = ribonuclease-inhibitor 1; TNF = tumor 
necrosis factor alpha  
38 
 
Figure 8 
 
Proposed pathway and pathophysiologic role of eRNA, RNase 1, and RNH1 in septic 
cardiomyopathy 
eRNA belongs to the heterogeneous group of DAMPs and is released as a result of sepsis-
associated tissue injury and necrotic cell death. eRNA binds to the pattern recognition receptors 
toll-like receptor 3 located on the endosome, which results in the formation of TNF in 
cardiomyocytes. TNF binds to TNFR and induces pro-apoptotic as well as pro-inflammatory 
pathways. RNases belong to a group of host-defense peptides secreted from endothelial cells 
and thereby cleave eRNA. RNH1 binds to RNase 1 and inactivates the host-defense function 
of RNases, which allows eRNA to bind to TLR. eRNA = extracellular RNA; RNase 1 = 
ribonuclease 1; RNH1 = ribonuclease-inhibitor 1; TNF = tumor necrosis factor alpha; TLR = 
toll-like receptor; TNFR = tumor necrosis factor receptor 
 
